Anil K Chaturvedi1, Gypsyamber D'Souza2, Maura L Gillison3, Hormuzd A Katki4. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, USA. Electronic address: chaturva@mail.nih.gov. 2. Johns Hopkins University, Bloomberg School of Public Health, Baltimore, USA. 3. The Ohio State University, Columbus, USA. 4. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, USA.
Abstract
BACKGROUND: HPV-positive oropharynx cancer is frequently characterized as a disease of never-smokers due to higher HPV prevalence in oropharynx tumors among never-smokers than ever-smokers. We sought to estimate the burden (incidence rates and case counts) of HPV-positive oropharynx cancers among never, former, and current smokers in the US population by combining data from several sources. METHODS: We decomposed the SEER population-level incidence of oropharynx cancers into rates among never-, former-, and current-smokers using a formula based upon rate ratios (RR) for the smoking-oropharynx cancer association (NIH-AARP cohort study) and smoking prevalence in the U.S. population (NHANES 2007/2008). These rates were multiplied by smoking strata-specific HPV prevalence in oropharynx cancer patients (RTOG0129) to estimate incidence of HPV-positive and HPV-negative oropharynx cancers, which were applied to the US population of smokers to calculate annual case counts. Analyses were conducted overall and gender-stratified. RESULTS: The incidence of HPV-positive oropharynx cancers was significantly higher among ever versus never-smokers in the US population aged 20+ years during 2007/2008 (RR=1.81; 95%CI=1.32-2.47), including significantly higher incidence in current smokers (RR=2.26; 95%CI=1.60-3.21) and former smokers (RR=1.38; 95%CI=1.02-1.85). Of the estimated 6677 (5418 in men and 1259 in women) annually incident HPV-positive oropharynx cancers in the U.S during 2007/2008, 63.3% arose among ever smokers and 36.7% among never-smokers (p<0.001). In both men and women, incidence rates and annual cases of HPV-positive oropharynx cancers were higher in ever smokers versus never smokers. CONCLUSIONS: The population-level burden of HPV-positive oropharynx cancers is significantly higher among ever-smokers than never-smokers in the U.S. Published by Elsevier Ltd.
BACKGROUND: HPV-positive oropharynx cancer is frequently characterized as a disease of never-smokers due to higher HPV prevalence in oropharynx tumors among never-smokers than ever-smokers. We sought to estimate the burden (incidence rates and case counts) of HPV-positive oropharynx cancers among never, former, and current smokers in the US population by combining data from several sources. METHODS: We decomposed the SEER population-level incidence of oropharynx cancers into rates among never-, former-, and current-smokers using a formula based upon rate ratios (RR) for the smoking-oropharynx cancer association (NIH-AARP cohort study) and smoking prevalence in the U.S. population (NHANES 2007/2008). These rates were multiplied by smoking strata-specific HPV prevalence in oropharynx cancerpatients (RTOG0129) to estimate incidence of HPV-positive and HPV-negative oropharynx cancers, which were applied to the US population of smokers to calculate annual case counts. Analyses were conducted overall and gender-stratified. RESULTS: The incidence of HPV-positive oropharynx cancers was significantly higher among ever versus never-smokers in the US population aged 20+ years during 2007/2008 (RR=1.81; 95%CI=1.32-2.47), including significantly higher incidence in current smokers (RR=2.26; 95%CI=1.60-3.21) and former smokers (RR=1.38; 95%CI=1.02-1.85). Of the estimated 6677 (5418 in men and 1259 in women) annually incident HPV-positive oropharynx cancers in the U.S during 2007/2008, 63.3% arose among ever smokers and 36.7% among never-smokers (p<0.001). In both men and women, incidence rates and annual cases of HPV-positive oropharynx cancers were higher in ever smokers versus never smokers. CONCLUSIONS: The population-level burden of HPV-positive oropharynx cancers is significantly higher among ever-smokers than never-smokers in the U.S. Published by Elsevier Ltd.
Authors: Daniel J Ma; Katharine A Price; Eric J Moore; Samir H Patel; Michael L Hinni; Joaquin J Garcia; Darlene E Graner; Nathan R Foster; Brenda Ginos; Michelle Neben-Wittich; Yolanda I Garces; Ashish V Chintakuntlawar; Daniel L Price; Kerry D Olsen; Kathryn M Van Abel; Jan L Kasperbauer; Jeffrey R Janus; Mark Waddle; Robert Miller; Satomi Shiraishi; Robert L Foote Journal: J Clin Oncol Date: 2019-06-04 Impact factor: 44.544
Authors: Nosayaba Osazuwa-Peters; Eric Adjei Boakye; Betty Y Chen; Betelihem B Tobo; Mark A Varvares Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-01-01 Impact factor: 6.223
Authors: Aimée R Kreimer; Anil K Chaturvedi; Laia Alemany; Devasena Anantharaman; Freddie Bray; Mary Carrington; John Doorbar; Gypsyamber D'Souza; Carole Fakhry; Robert L Ferris; Maura Gillison; D Neil Hayes; Allan Hildesheim; Shao Hui Huang; Luiz P Kowalski; Krystle A Lang Kuhs; James Lewis; Douglas R Lowy; Hisham Mehanna; Andy Ness; Michael Pawlita; Maisa Pinheiro; John Schiller; Meredith S Shiels; Joseph Tota; Lisa Mirabello; Saman Warnakulasuriya; Tim Waterboer; William Westra; Stephen Chanock; Paul Brennan Journal: Oral Oncol Date: 2020-06-02 Impact factor: 5.337